Exhibit 99.1 32301 Woodward Ave. Royal Oak, MI 48073 www.agreerealty.com FOR IMMEDIATE RELEASE Agree Realty Corporation Reports Fourth Quarter and Full Year 2024 Results Provides Initial 2025 AFFO Per Share Guidance of $4.26 to $4.30 Royal Oak, MI, February 11, 2025 -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced results for the quarter and full year ended December 31, 2024. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Fourth ...

Provides Initial 2025 AFFO Per Share Guidance of $4.26 to $4.30ROYAL OAK, Mich., Feb. 11, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced results for the quarter and full year ended December 31, 2024. All per share amounts included herein are on a diluted per common share basis unless otherwise stated.Fourth Quarter 2024 Financial and Operating Highlights: Invested approximately $371 million in 127 retail net lease properties Commenced eight development or Developer ...

At the core, Agree Realty (ADC 0.27%) and Realty Income (O -0.26%) are very similar real estate investment trusts (REITs). But they aren't interchangeable. Here's why some investors will like Agree, while others will favor Realty Income. It all boils down to the growth these two monthly dividend payers can offer to shareholders.Why go with Realty Income?A net lease requires tenants to pay most property-level operating costs. Net lease assets are usually occupied by a single tenant, so the risk for any indiv ...

In its upcoming report, Agree Realty (ADC) is predicted by Wall Street analysts to post quarterly earnings of $1.03 per share, reflecting an increase of 3% compared to the same period last year. Revenues are forecasted to be $159.53 million, representing a year-over-year increase of 10.7%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over ...

Net leases obligate the tenant to pay for all or most property maintenance, taxes, and insurance. They're typically applied to single-tenant, freestanding properties that were usually built or retrofitted toIf you want access to our entire Portfolio and all our current Top Picks, feel free to join us for a 2-week free trial at High Yield Landlord.We are the largest real estate investment community on Seeking Alpha with over 2,000 members on board and a perfect 5/5 rating from 400+ reviews:For a Limited Time ...

Group 1 - Samuel Smith has extensive experience in dividend stock research and investment, having served as lead analyst and Vice President at notable firms [1] - He is a Professional Engineer and Project Management Professional with degrees in Civil Engineering & Mathematics and a Master's in Engineering focused on applied mathematics and machine learning [1] - Samuel leads the High Yield Investor investing group, collaborating with Jussi Askola and Paul R. Drake to balance safety, growth, yield, and value in investment strategies [2] Group 2 - High Yield Investor provides real-money core, retirement, and international portfolios, along with regular trade alerts and educational content for investors [2] - The service includes an active chat room for like-minded investors to share insights and strategies [2]

Group 1 - High Yield Investor offers a portfolio that has consistently outperformed the market, providing a 2-week free trial for potential investors [1] - Samuel Smith, a lead analyst and Vice President with a strong background in dividend stock research, leads the High Yield Investor group, focusing on safety, growth, yield, and value [2] - The investment group provides real-money core, retirement, and international portfolios, along with regular trade alerts and educational content [2] Group 2 - The article emphasizes that past performance is not indicative of future results, and no specific investment recommendations are made [4]

Core Viewpoint - Agree Realty is recommended as a strong dividend stock due to its high yield, growth potential, and stable business model, with the added benefit of paying monthly dividends [1] Company Overview - Agree Realty is a retail real estate investment trust (REIT) that leases properties primarily to large chain retailers, ensuring reliable rental income [2][3] - The company owns 2,370 properties across 50 states, with Walmart being its largest tenant, accounting for 6.3% of its portfolio [4] Growth Opportunities - Established in 1971, Agree Realty has a long history of reliability and significant growth opportunities due to its relatively small size [5] - The company focuses on tenants with omnichannel capabilities, integrating e-commerce with physical retail, and has launched a campaign called Rethink Retail to address misconceptions about physical retail's future [6] Acquisition Strategy - Management has identified numerous excellent properties for acquisition, having acquired $341 million worth of properties in Q4 2024, with estimated acquisition spending of $1.1 billion to $1.3 billion for 2025 [7] - The company has approximately $2 billion in liquidity, including $900 million in forward equity and $1.1 billion in revolving credit, with no material debt maturities until 2028 [8] Dividend Performance - Agree Realty offers a dividend yield of 4.2%, significantly higher than the S&P 500 average, with a compound annual growth rate of 6% over the past decade [9] - The stock has increased by 26% over the past year, with healthy growth reported despite industry challenges, including a 2.8% year-over-year increase in adjusted funds from operations in Q3 [10] Investment Perspective - As a REIT, Agree Realty is primarily viewed as a source of reliable passive income rather than a growth stock, making it a strong choice for investors seeking dividend stocks [11]

Market Overview - REITs are currently trading at the largest discount since the 2008 financial crisis, indicating a significant undervaluation in the sector [1] - The equity market's daily price fluctuations contribute to long-term wealth creation or destruction, highlighting the importance of strategic investment [1] Investment Strategy - Pacifica Yield focuses on long-term wealth creation by targeting undervalued yet high-growth companies, high-dividend tickers, REITs, and green energy firms [1] Analyst Position - The analyst holds a beneficial long position in Agree Realty's (NYSE: ADC) common shares, including stock ownership, options, or other derivatives [2]

Core Insights - Innovent Biologics has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for IBI343, an anti-CLDN18.2 antibody-drug conjugate (ADC), aimed at treating advanced pancreatic ductal adenocarcinoma (PDAC) patients who have progressed after prior treatments [1][2][8] - The designation was based on promising results from an ongoing Phase 1 study, which showed favorable safety, tolerability, and antitumor activity of IBI343 in advanced PDAC patients [2][3] - IBI343 has also received Fast Track Designation from the U.S. FDA for treating advanced, unresectable or metastatic PDAC that has relapsed or is refractory to one prior line of therapy [2][8] Company Overview - Innovent Biologics is a biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for various serious diseases, including oncology, cardiovascular, and autoimmune conditions [9] - The company has launched 13 products and has multiple assets in various stages of clinical trials, including 4 new drug applications under regulatory review [9] - Innovent collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [9] Industry Context - Pancreatic cancer is characterized by a low 5-year survival rate of approximately 10%, with limited treatment options leading to poor patient outcomes [4] - Current therapies primarily involve systemic chemotherapy, with second-line treatment options yielding a chemotherapy response rate of only 6-16% and a median overall survival of about 6 to 9 months [4] - The presence of CLDN18.2 in 50% to 70% of pancreatic cancer cases makes it a significant target for therapeutic development, highlighting the need for innovative treatments like IBI343 [6][7]